220
Participants
Start Date
October 31, 2007
Primary Completion Date
September 30, 2010
Study Completion Date
September 30, 2010
AT-101, prednisone and docetaxel
docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3
placebo, prednisone and docetaxel
docetaxel (75mg/m2 intravenously over 1 hour every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
Colorado Springs
New Port Richey
Ocoee
Fishers
Burnsville
Las Vegas
Albuquerque
Las Cruces
Raleigh
Kettering
Eugene
Spartanburg
Amarillo
Arlington
Austin
Dallas
Denton
Midland
Paris
Webster
Fairfax
Norfolk
Kennewick
Vancouver
Barnaul
Engel's
Kazan'
Kursk
Kuzmolovsky
Moscow
Saint Petersburg
Sochi
Stavropol
Voronezh
Yekaterinburg
Lead Sponsor
Ascenta Therapeutics
INDUSTRY